Author

Muhammad Usman

Carl von Ossietzky Universität Oldenburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Charlotte Luise Kluth· 1 shared Christoph Jüschke· 1 shared Dennis Kastrati· 1 shared Jannis Marticke· 1 shared John NeidhardtiD· 1 shared Julia Milena Brinkhoff· 1 shared Paul AtigbireiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Charlotte Luise Kluth

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The human-specific RPGR isoform RPGRs14/15 and the clinically approved Rho/ROCK inhibitor Ripasudil represent therapeutic options to address RPGR-associated defects.

Muhammad Usman, Paul Atigbire, Dennis Kastrati, Julia Milena Brinkhoff, Charlotte Luise Kluth, Jannis Marticke, Christoph Jüschke, John Neidhardt

This study identifies the human-specific RPGR isoform RPGRs14/15 and the drug Ripasudil as potential therapies for RPGR-associated retinal degeneration by rescuing ciliary and actin defects in RPGR mutant cells.

bioRxiv · May 9, 2025 · PreprintCell Biology